Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression

The aim of the current study was to investigate whether the levels of mRNA expression of brain-derived neurotrophin factor (BDNF) and a related gene MEK1 were more obviously decreased in treatment-resistant depression (TRD). In total, 50 patients with major depressive disorder (including 26 with TRD and 24 with treatment-responsive depression) and 48 healthy controls were enrolled. BDNF and MEK1 mRNA levels in blood samples from all patients and controls were measured using reverse transcriptase-PCR. BDNF and MEK1 mRNA levels were significantly reduced in patients with major depressive disorder when compared with healthy controls (BDNF: P<0.01; MEK1: P<0.001), as well as among treatment-resistant depressive patients as compared with treatment-responsive depressive patients (BDNF: P<0.001; MEK1: P<0.01). Our findings support the hypothesis that BDNF and MEK1 mRNA expression levels are more obviously decreased in patients with TRD.

[1]  Chen Zhang,et al.  Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. , 2014, Journal of affective disorders.

[2]  D. Charney,et al.  Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. , 2014, The international journal of neuropsychopharmacology.

[3]  Chen Zhang,et al.  A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression , 2014, Psychopharmacology.

[4]  R. Yoshimura,et al.  Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD) , 2012, CNS Spectrums.

[5]  B. Spivak,et al.  The economic impact of depression: Resistance or severity? , 2010, European Neuropsychopharmacology.

[6]  M. Riva,et al.  Serum and plasma BDNF levels in major depression: A replication study and meta-analyses , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[7]  H. Manji,et al.  Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. , 2010, Journal of affective disorders.

[8]  E. Castrén,et al.  The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity , 2010, Developmental neurobiology.

[9]  Yogesh K. Dwivedi,et al.  Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. , 2008, The international journal of neuropsychopharmacology.

[10]  E. Roubos,et al.  Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression , 2008, Neuroscience.

[11]  P. Deloukas,et al.  The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans , 2007, Neuroreport.

[12]  Sun-Hwa Park,et al.  Decreased plasma BDNF level in depressive patients. , 2007, Journal of affective disorders.

[13]  Changsu Han,et al.  Low plasma BDNF is associated with suicidal behavior in major depression , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[15]  A. Rush,et al.  Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. , 2006, The Journal of clinical psychiatry.

[16]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[17]  Alexis J. Kant,et al.  Treatment resistant depression and Axis I co-morbidity , 2001, Psychological Medicine.

[18]  Y. Fang,et al.  The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. , 2013, Journal of psychiatric research.

[19]  R. Shelton,et al.  Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. , 2009, Journal of psychiatric research.